Pfizer Secures Vyndamax Patent Exclusivity Through 2031

Pfizer Inc. (PFE) announced Tuesday that it has resolved patent litigation with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla regarding Vyndamax, its leading therapy for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The settlement agreements effectively extend the U.S. patent expiry for the drug to June 1, 2031, although the final date remains subject to the outcomes of other ongoing litigation. This legal victory provides a critical buffer for Pfizer's long-term financial projections. The company had previously anticipated a decline in revenue beginning in 2029 as patent protections were expected to lapse. Under the new terms, Pfizer now expects U.S. sales for the therapy to remain relatively stable from 2028 through the first half of 2031. Vyndamax currently dominates the ATTR-CM market, commanding approximately 75% of the total prescription volume. The once-daily medication is highly valued in the clinical community for its demonstrated ability to significantly reduce all-cause mortality and cardiovascular-related hospitalizations. By delaying the entry of generic competitors, Pfizer secures a multi-year window of exclusivity for one of its key specialty medicines. This outcome mitigates immediate pressure on the company's portfolio as it manages its broader pipeline of expiring patents.